Venous and arterial thrombosis in patients with HIV infection

Thromboembolic complications in HIV-infected patients have been reported. To our knowledge, no case–control studies have compared the prevalence of thromboembolic events between HIV-positive and HIV-negative individuals. One hundred and sixty-nine HIV-infected patients and 180 randomly selected blood donors were enrolled. Selected patients completed a specific questionnaire and were subsequently interviewed. Information was collected on family and personal history of cardiovascular disorders and the presence of personal risk factors for venous and arterial thrombosis. All reported events were adjudicated only if adequate documentation of objective tests was available. Mean age and sex were similar in the two groups. A vascular event was documented in six HIV-infected patients (3.55%) and in none of the controls (P = 0.0108). Family history of cardiovascular disorders, cigarette smoking and hypertriglyceridemia were more prevalent in HIV patients than in controls. In multivariate analysis, neither family traditional cardiovascular risk factors nor HIV infection were independently associated with the presence of thromboembolic events. The results confirm the hypothesis that HIV-positive patients have an increased risk of thromboembolic disorders. Whether this increased risk has been provoked by HIV infection itself or by other associated risk factors for cardiovascular events, such as cigarette smoking and hypertriglyceridemia, remain to be clarified.

[1]  B. Bozkurt.  Cardiovascular toxicity with highly active antiretroviral therapy , 2007, Cardiovascular Toxicology.

[2]  W. K. Henry,et al.  Carotid artery intima–media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure , 2005, AIDS.

[3]  J. Margolick,et al.  Human immunodeficiency virus 1 infection, cocaine, and coronary calcification. , 2005, Archives of internal medicine.

[4]  Jeffrey N. Martin,et al.  Progression of Atherosclerosis as Assessed by Carotid Intima-Media Thickness in Patients With HIV Infection , 2004, Circulation.

[5]  M. Schambelan,et al.  The metabolic effects of lopinavir/ritonavir in HIV-negative men , 2004, AIDS.

[6]  J. Cristol,et al.  Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. , 2004, Atherosclerosis.

[7]  D. Waters,et al.  Clinical Features of Acute Coronary Syndromes in Patients With Human Immunodeficiency Virus Infection , 2004, Circulation.

[8]  R. Colebunders,et al.  Mixed Arterial and Venous Thromboembolism in a Person with HIV Infection , 2003, Scandinavian journal of infectious diseases.

[9]  Rodolphe Thiébaut,et al.  Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .

[10]  Jeffrey N. Martin,et al.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. , 2003, The Journal of infectious diseases.

[11]  Leonardo Calza,et al.  Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART , 2003, AIDS.

[12]  S. Kaul,et al.  Acute myocardial infarction in human immunodeficiency virus-infected patients. , 2003, Archives of internal medicine.

[13]  T. Louis,et al.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. , 2003, The New England journal of medicine.

[14]  Girish Modi,et al.  Stroke in Black South African HIV-Positive Patients: A Prospective Analysis , 2003, Stroke.

[15]  Dannae Brown,et al.  A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia , 2002, AIDS.

[16]  S. Sidney,et al.  Do Protease Inhibitors Increase the Risk for Coronary Heart Disease in Patients With HIV‐1 Infection? , 2002, Journal of acquired immune deficiency syndromes.

[17]  John M Williamson,et al.  Protease inhibitors and cardiovascular outcomes in patients with HIV-1 , 2002, The Lancet.

[18]  C. Tinelli,et al.  Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. , 2002, Atherosclerosis.

[19]  P. Homel,et al.  HIV infection is a risk factor for venous thromboembolism. , 2002, AIDS patient care and STDs.

[20]  M. Schambelan,et al.  Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study , 2002, AIDS.

[21]  N. Christeff,et al.  Increased serum interferon alpha in HIV–1 associated lipodystrophy syndrome , 2002, European journal of clinical investigation.

[22]  B. Gazzard,et al.  Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy , 2001, AIDS.

[23]  P. McBride,et al.  Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction , 2001, Circulation.

[24]  V. Hombach,et al.  C-Reactive Protein–Mediated Low Density Lipoprotein Uptake by Macrophages: Implications for Atherosclerosis , 2001, Circulation.

[25]  A. Telenti,et al.  Premature atherosclerosis in HIV-infected individuals – focus on protease inhibitor therapy , 2001, AIDS.

[26]  J. Weiel,et al.  HIV Protease Inhibitors Stimulate Hepatic Triglyceride Synthesis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[27]  G. Serio,et al.  Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors , 2000, AIDS.

[28]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[29]  G. Schulte-Altedorneburg,et al.  Cerebral vasculopathy in HIV infection revealed by transcranial Doppler: A pilot study. , 1999, Stroke.

[30]  K. Henry,et al.  Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities , 1998, The Lancet.

[31]  K. Henry,et al.  Severe premature coronary artery disease with protease inhibitors , 1998, The Lancet.

[32]  K. Feingold,et al.  Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome. , 1997, The Journal of clinical endocrinology and metabolism.

[33]  C. Lasseur,et al.  Asymptomatic atherosclerosis in HIV-positive patients: A case-control ultrasound study. , 1995, Annals of medicine.

[34]  C. Grunfeld,et al.  Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. , 1993, The Journal of clinical endocrinology and metabolism.

[35]  K. Feingold,et al.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. , 1992, The Journal of clinical endocrinology and metabolism.